GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The company has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
Follow-Up Questions
Globeimmune Inc의 CEO는 누구입니까?
Dr. Timothy Rodell은 2003부터 회사에 합류한 Globeimmune Inc의 President입니다.
GBIM 주식의 가격 성능은 어떻습니까?
GBIM의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Globeimmune Inc의 주요 사업 주제나 업종은 무엇입니까?
Globeimmune Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
